Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications

@article{Nyandege2015RiskOF,
  title={Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications},
  author={A. Nyandege and P. Slattum and S. Harpe},
  journal={Annals of Pharmacotherapy},
  year={2015},
  volume={49},
  pages={437 - 447}
}
  • A. Nyandege, P. Slattum, S. Harpe
  • Published 2015
  • Medicine
  • Annals of Pharmacotherapy
  • Objective: To review the literature on the concomitant use of bisphosphonates and medications that can influence bone metabolism and potentially attenuate bisphosphonate antifracture efficacy. Data Sources: MEDLINE and CINAHL were searched for articles published in English through December 2014 using the following terms: bisphosphonates, bone density conservation agents, acid-suppressive therapy, levothyroxine, thiazolidinediones (TZDs), selective serotonin reuptake inhibitors (SSRIs), bone… CONTINUE READING
    Guidelines for the diagnosis, prevention and management of osteoporosis.
    • 94
    • Highly Influenced
    • PDF
    Bergapten promotes bone marrow stromal cell differentiation into osteoblasts in vitro and in vivo
    • 7

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 60 REFERENCES
    Meta-analysis: risk of fractures with acid-suppressing medication.
    • 98
    • PDF
    Proton pump inhibitor use and the antifracture efficacy of alendronate.
    • 80
    • Highly Influential
    • PDF